Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

Paolo Ferrigno Product Manager prefilled syringes and cartridges Datwyler Healthcare ...

Merck (MRK) stock gains as Wolfe Research upgrades the company to Outperform, while AbbVie (ABBV) falls as the firm ...

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...

MannKind closed 2025 on a high note, marked by milestones that reinforce our growth trajectory—including the acquisition of scPharmaceuticals and a record-setting fourth quarter surpassing $100 ...

A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual ...

Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the Company entered into a global collaboration and exclusive ...

Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US ...

KalVista launched Ekterly in the U.S. in July for the treatment of acute attacks of hereditary angioedema in adults and ...

Halozyme Therapeutics has had an impressive run over the past six months as its shares have beaten the S&P 500 by 24.3%. The ...

Wolfe is bullish on Merck & Company Inc (NYSE:MRK) while stepping back from AbbVie Inc (NYSE:ABBV). Analysts say the market is underestimating Merck’s ability to grow beyond Keytruda and has already ...

Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme Therapeutics ...